scRNAseq Demands You to Be a Researcher, Coder, and Innovator
Via Foundry makes it possible to excel in all three without the complexity Single-cell RNA...
Vitiligo has been a mystery for biologists forever. It is a complex autoimmune disease linked to genetics, but that’s not the whole story.
Genetics alone doesn’t explain the complexity of vitiligo. Studies on identical twins reveal that only one in four pairs both have the condition. The remaining pairs often see only one twin affected, and this indicates that factors beyond genetics, such as stress and trauma like sunburn, also play significant roles.
At our medical school, UMass Chan, my colleagues who have been studying vitiligo have recently launched a new project to understand these complexities. VIGOR, or Vitiligo Impact of Family Groups: Observation and Research, is a groundbreaking initiative designed to understand why vitiligo occurs and how it can be treated more effectively.
This ambitious project will span at least five years, potentially more, enrolling 200 people with vitiligo and 800 of their close relatives who do not have the condition. If you have family members with vitiligo, you can also join the study here.
Participants will regularly submit saliva, blood, and skin samples, along with surveys about their lifestyle, stress levels, illnesses, and chemical exposures.
These self-collected samples will be sent to UMass Chan labs, where the team will track the data over the years, identifying which individuals without vitiligo eventually develop the condition. This will help them understand the mix of genetic and environmental factors that cause vitiligo.
A unique aspect of the VIGOR study is its proactive approach to understanding and preventing vitiligo.
By closely monitoring individuals who are genetically predisposed but have not yet developed the condition, researchers aim to identify early biomarkers and potential triggers. This could lead to preventive strategies, allowing for interventions before vitiligo manifests.
The goal is to develop treatments that can halt the disease in its tracks, providing hope for those at risk and potentially reducing the incidence of vitiligo in future generations.
Understanding the role of environmental factors is crucial. The VIGOR project not only focuses on genetic predispositions but also examines how external factors like chemical exposures, stress, and trauma can contribute to the onset of vitiligo.
The study collects detailed data on participants’ lifestyles and environments, and this will show us how these factors interact with genetics to cause the disease. As a result of this comprehensive approach, we’ll gain a complete understanding of what triggers vitiligo.
The VIGOR project is a major effort to understand the complexities of vitiligo. With advanced research methods and extensive data collection, we will uncover the many causes of this condition. This knowledge will eventually lead to new treatments and preventive measures and greatly improve the lives of those with vitiligo and their families.
Handling such vast amounts of data over an extended period is difficult. Technology evolves rapidly; in five years, many of today’s applications will become obsolete. One or two scientists may have to leave the project for any reason. So data management and consistency is a potential issue.
Additionally, patient anonymity must be maintained, adding another layer of complexity to data handling.
Fortunately, our colleagues at UMass Chan have a powerful tool at their disposal: Foundry, which I’m proud to be one of the founders of. Over a decade ago, my team and I started developing what was initially known as DolphinNext. Recently, we rebranded it as Foundry under Via Scientific.
Foundry is now the world’s most comprehensive science platform. As biologists who understand the unique challenges of our field, we designed Foundry to meet these needs precisely.
Foundry simplifies the management of large-scale, long-term studies like VIGOR. It supports the integration and analysis of multi-omics data, eliminating bioinformatics and coding bottlenecks that often slow scientific advancement. Here’s how Foundry, enhanced by AI, excels in supporting the VIGOR study:
Foundry offers a suite of tools tailored for scientists, bioinformaticians, and computational biologists. It simplifies data integration, workflow creation, and analysis, making it an invaluable asset for complex research projects like VIGOR. Foundry’s key benefits include:
The VIGOR study represents a monumental effort to unravel the complexities of vitiligo. Supported by the AI-enhanced Foundry platform, this research has the potential to transform our understanding and treatment of this challenging condition.
As part of the Via Scientific team, I am proud to make this study possible. We are confident that the insights gained from this study will not only advance vitiligo research but also set a precedent for using AI to understand other complex autoimmune and genetic disorders. Together, we’re advancing science and technology to solve the mysteries of human health.
(*) Via Scientific, Inc., a new Cambridge-based technology and AI company, has launched Via Foundry, a multi-omics accelerator platform designed to accelerate scientific breakthroughs. Originally developed over a decade at UMass Chan Medical School by scientists, Via Foundry is now exclusively commercialized by Via Scientific. The company was founded by a team of experts including Melissa J. Moore, PhD, Alper Kucukural, PhD, Manuel Garber, PhD, Jim Crowley, and Janet Kosloff.
Via Foundry automates the complex data and analytical tasks involved in multi-omics research with features like a drag-and-drop pipeline, metadata building functionality, and customizable analytics, eliminating the need for coding. This platform ensures data is shareable, reusable, and reproducible, allowing researchers to focus on core scientific insights and therapeutic breakthroughs.
Via Scientific aims to support biotech, pharmaceutical companies, research institutes, and academic universities while enhancing the AI capabilities of the Via Foundry platform.
Via Scientific Inc., a Cambridge-based tech and AI company, has launched Via Foundry, a multi-omics accelerator platform designed to advance scientific breakthroughs. Via Foundry automates complex data tasks with features like drag-and-drop pipelines and customizable analytics, ensuring data is shareable, reusable, and reproducible, allowing researchers to focus on scientific insights instead of code. Via Scientific supports biotech, pharma, research institutes, and universities.
Via Foundry makes it possible to excel in all three without the complexity Single-cell RNA...
Via Foundry makes it possible to excel in all three without the complexity Single-cell RNA...
The criticality of seamless collaboration in research The fields of medical science, life sciences, and...
The criticality of seamless collaboration in research The fields of medical science, life sciences, and...
Adding a new dimension to multi-omics with Via Foundry’s advanced technology for RNA Therapeutics RNA...
Adding a new dimension to multi-omics with Via Foundry’s advanced technology for RNA Therapeutics RNA...